Who are Lipofundin MCT 20%'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): OLIVE OIL, SOYBEAN OIL, MCT/LCT (1:1), bran oil, SMOFlipid + Omegaven, SMOFlipid.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lipofundin-mct-20.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Lipofundin MCT 20% — Competitive Intelligence Brief

Lipofundin MCT 20% (Lipofundin MCT 20%) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Lipid emulsion; parenteral nutrition supplement. Area: Nutrition support; Critical care.

marketed Lipid emulsion; parenteral nutrition supplement Nutrition support; Critical care Small molecule Live · refreshed every 30 min

Target snapshot

Lipofundin MCT 20% (Lipofundin MCT 20%) — B. Braun Melsungen AG. Lipofundin MCT 20% is a lipid emulsion that provides essential fatty acids and calories for parenteral nutrition in patients unable to eat or absorb nutrients orally.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Approval / PDUFA
Lipofundin MCT 20% TARGET	Lipofundin MCT 20%	B. Braun Melsungen AG	marketed	Lipid emulsion; parenteral nutrition supplement
OLIVE OIL	OLIVE OIL		marketed	Lipid Emulsion [EPC]	2013-01-01
SOYBEAN OIL	SOYBEAN OIL		marketed	Lipid Emulsion [EPC]	1982-01-01
MCT/LCT (1:1)	MCT/LCT (1:1)	B. Braun Medical SA	marketed	Lipid emulsion for parenteral nutrition
bran oil	bran oil	Indonesia University	marketed	Lipid Emulsion [EPC]
SMOFlipid + Omegaven	SMOFlipid + Omegaven	General University Hospital, Prague	marketed	Lipid emulsion / Parenteral nutrition supplement
SMOFlipid	SMOFlipid	Baylor College of Medicine	marketed	Lipid Emulsion [EPC]

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Lipid emulsion; parenteral nutrition supplement class)

B. Braun Melsungen AG · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lipofundin MCT 20% — Competitive Intelligence Brief. https://druglandscape.com/ci/lipofundin-mct-20. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab